FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2806696712> ?p ?o ?g. }

• W2806696712 endingPage "69.e2" @default.
• W2806696712 startingPage "60" @default.
• W2806696712 abstract "The optimal long-term dosing strategy for adalimumab (ADA) in hidradenitis suppurativa/acne inversa (HS) was evaluated by pooling the results of the PIONEER phase 3 trials and an open-label extension (OLE) study.To assess the response to and tolerability of long-term administration of ADA in HS.The durations of the PIONEER I/II periods A, B, and OLE were 12, 24, and 52 or more weeks, respectively. Patients who entered the OLE and received ADA (40 mg every week continuously) and responders plus partial responders (PRRs) were evaluated. Primary efficacy assessments included measurement of HS clinical response (HiSCR), lesion counts, skin pain, and Dermatology Life Quality Index (DLQI). Treatment-emergent adverse events were assessed.At week 12, 52.3% of those receiving ADA weekly and 73.0% of PRRs achieved HiSCR. Achievement of HiSCR was maintained through week 168 in 52.3% of patients who received ADA weekly and 57.1% of PRRs. Sustained improvement in lesion counts, skin pain, and DLQI score were also observed. The safety profile throughout the OLE was similar to the profiles observed in the PIONEER studies.The OLE was uncontrolled.Continuous weekly dosing with ADA, 40 mg, is a reasonable treatment option for long-term control of moderate-to-severe HS." @default.
• W2806696712 created "2018-06-13" @default.
• W2806696712 creator A5000398504 @default.
• W2806696712 creator A5007042386 @default.
• W2806696712 creator A5007302064 @default.
• W2806696712 creator A5019749903 @default.
• W2806696712 creator A5020627620 @default.
• W2806696712 creator A5021906179 @default.
• W2806696712 creator A5035579371 @default.
• W2806696712 creator A5056346259 @default.
• W2806696712 creator A5064550852 @default.
• W2806696712 creator A5087050293 @default.
• W2806696712 date "2019-01-01" @default.
• W2806696712 modified "2023-10-11" @default.
• W2806696712 title "Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study" @default.
• W2806696712 cites W1867780443 @default.
• W2806696712 cites W1919599643 @default.
• W2806696712 cites W1970785085 @default.
• W2806696712 cites W1975884572 @default.
• W2806696712 cites W1996601924 @default.
• W2806696712 cites W1999378785 @default.
• W2806696712 cites W2058562555 @default.
• W2806696712 cites W2074260096 @default.
• W2806696712 cites W2091683231 @default.
• W2806696712 cites W2104111543 @default.
• W2806696712 cites W2110755088 @default.
• W2806696712 cites W2133633410 @default.
• W2806696712 cites W2149371387 @default.
• W2806696712 cites W2257937652 @default.
• W2806696712 cites W2266330333 @default.
• W2806696712 cites W2284148347 @default.
• W2806696712 cites W2503109448 @default.
• W2806696712 cites W2517109673 @default.
• W2806696712 cites W2694182897 @default.
• W2806696712 doi "https://doi.org/10.1016/j.jaad.2018.05.040" @default.
• W2806696712 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29860040" @default.
• W2806696712 hasPublicationYear "2019" @default.
• W2806696712 type Work @default.
• W2806696712 sameAs 2806696712 @default.
• W2806696712 citedByCount "114" @default.
• W2806696712 countsByYear W28066967122018 @default.
• W2806696712 countsByYear W28066967122019 @default.
• W2806696712 countsByYear W28066967122020 @default.
• W2806696712 countsByYear W28066967122021 @default.
• W2806696712 countsByYear W28066967122022 @default.
• W2806696712 countsByYear W28066967122023 @default.
• W2806696712 crossrefType "journal-article" @default.
• W2806696712 hasAuthorship W2806696712A5000398504 @default.
• W2806696712 hasAuthorship W2806696712A5007042386 @default.
• W2806696712 hasAuthorship W2806696712A5007302064 @default.
• W2806696712 hasAuthorship W2806696712A5019749903 @default.
• W2806696712 hasAuthorship W2806696712A5020627620 @default.
• W2806696712 hasAuthorship W2806696712A5021906179 @default.
• W2806696712 hasAuthorship W2806696712A5035579371 @default.
• W2806696712 hasAuthorship W2806696712A5056346259 @default.
• W2806696712 hasAuthorship W2806696712A5064550852 @default.
• W2806696712 hasAuthorship W2806696712A5087050293 @default.
• W2806696712 hasConcept C126322002 @default.
• W2806696712 hasConcept C141071460 @default.
• W2806696712 hasConcept C16005928 @default.
• W2806696712 hasConcept C197934379 @default.
• W2806696712 hasConcept C2776002364 @default.
• W2806696712 hasConcept C2776173921 @default.
• W2806696712 hasConcept C2777288759 @default.
• W2806696712 hasConcept C2777673923 @default.
• W2806696712 hasConcept C2778375690 @default.
• W2806696712 hasConcept C2779134260 @default.
• W2806696712 hasConcept C2780132546 @default.
• W2806696712 hasConcept C2780400711 @default.
• W2806696712 hasConcept C2780564577 @default.
• W2806696712 hasConcept C2781464078 @default.
• W2806696712 hasConcept C500558357 @default.
• W2806696712 hasConcept C71924100 @default.
• W2806696712 hasConceptScore W2806696712C126322002 @default.
• W2806696712 hasConceptScore W2806696712C141071460 @default.
• W2806696712 hasConceptScore W2806696712C16005928 @default.
• W2806696712 hasConceptScore W2806696712C197934379 @default.
• W2806696712 hasConceptScore W2806696712C2776002364 @default.
• W2806696712 hasConceptScore W2806696712C2776173921 @default.
• W2806696712 hasConceptScore W2806696712C2777288759 @default.
• W2806696712 hasConceptScore W2806696712C2777673923 @default.
• W2806696712 hasConceptScore W2806696712C2778375690 @default.
• W2806696712 hasConceptScore W2806696712C2779134260 @default.
• W2806696712 hasConceptScore W2806696712C2780132546 @default.
• W2806696712 hasConceptScore W2806696712C2780400711 @default.
• W2806696712 hasConceptScore W2806696712C2780564577 @default.
• W2806696712 hasConceptScore W2806696712C2781464078 @default.
• W2806696712 hasConceptScore W2806696712C500558357 @default.
• W2806696712 hasConceptScore W2806696712C71924100 @default.
• W2806696712 hasFunder F4320309117 @default.
• W2806696712 hasFunder F4320332418 @default.
• W2806696712 hasIssue "1" @default.
• W2806696712 hasLocation W28066967121 @default.
• W2806696712 hasLocation W28066967122 @default.
• W2806696712 hasOpenAccess W2806696712 @default.
• W2806696712 hasPrimaryLocation W28066967121 @default.
• W2806696712 hasRelatedWork W2800869485 @default.
• W2806696712 hasRelatedWork W2805791571 @default.

• next